News | Cardiovascular Business | February 28, 2022

Cardiovascular Disease Concerns Pump Sales of Cardiac Markers to $2.5 Billion

Healthcare publisher, Kalorama Information, shares insights from its latest report on the Cardiac Markers market

image of a heart

February 28, 2022 – Despite improvements in treatment and increased public awareness about prevention, cardiovascular disease (CVD) is still the leading cause of death worldwide. CVD causes half of all deaths in several developed countries and is the major cause of adult death in many developing countries. And though some cardiovascular events aren't fatal, strokes and other forms of heart disease may still be debilitating enough to seriously affect functional ability. These concerns are contributing to growth in sales of cardiac markers, according to World Market for Cardiac Markers (POC and Lab-Based), a recent report by medical market research firm Kalorama Information.

Cardiac markers generated an estimated $2.52 billion in sales during 2021, largely as a result of the prevalence of cardiovascular diseases, including those of the blood vessels supplying the heart muscle and the brain. Looking ahead, the market is forecast to increase by a compound annual growth rate (CAGR) of 4.1% between 2021-2026, reveals World Market for Cardiac Markers (POC and Lab-Based).

“With the incidence of cardiovascular disease going through the roof, cardiac markers are in huge demand and a constant subject of research for improvement,” said Bruce Carlson, publisher for Kalorama Information.

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. In patients with chronic heart failure, measurement of these biomarkers is used to help risk stratify, to assess treatment options, monitor progress, and guide in-hospital and post-discharge care.

Physicians use cardiac markers in two ways—to diagnose a cardiac event in a hospital emergency room (acute care) or to evaluate the risk of a cardiovascular event occurring. The traditional markers—BNP, troponin and myoglobin are used in the acute care and tests such as cholesterol are used to evaluate risk.

An aging population combined with advancements in technology are innovating the market as health care providers seek ways to meet the demand for high levels of service in a more cost-effective manner.

For more information: https://kaloramainformation.com/product/world-market-for-cardiac-markers-poc-and-lab-based/.

Related cardiovascular disease content:

A Decade of Women’s Heart Health, Reexamined

Two Elevated Biomarkers Distinguish Blacks with Resistant Hypertension

Adolescent Psychological Well-being Tied to Adult Risk of Cardiovascular Disease, Study Finds

Related Content

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of June ...

Home July 05, 2022
Home
News | Cardiovascular Business

June 28, 2022 — – Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

Home June 28, 2022
Home
News | Cardiovascular Business

June 22, 2022 — Dr. Thomas Forbes, an interventional cardiologist, has joined Joe DiMaggio Children’s Hospital as its ...

Home June 22, 2022
Home
News | Cardiovascular Business

June 7, 2022 — Michael Bowdish, MD, MS, a national leader in cardiac surgery and among a handful of cardiac surgeons ...

Home June 07, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of May ...

Home June 01, 2022
Home
News | Cardiovascular Business

May 25, 2022 — MedStar Heart & Vascular Institute announced that Thomas E. MacGillivray, MD, has been named physician ...

Home May 25, 2022
Home
News | Cardiovascular Business

May 16, 2022 — Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific ...

Home May 16, 2022
Home
News | Cardiovascular Business

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

Home May 12, 2022
Home
News | Cardiovascular Business

May 12, 2022 — NDA Partners General Manager, Eric Fish, announced today that Peter Mackrell, MD, a board certified ...

Home May 12, 2022
Home
News | Cardiovascular Business

May 11, 2022 — Vital Heart & Vein, a leading provider of cardiovascular and vein health, has named Gay Nord as its new ...

Home May 11, 2022
Home
Subscribe Now